Podium to Practice: ESMO® 2025 – Lung: Beamion LUNG 1

Podium to Practice: ESMO® 2025 – Lung: Beamion LUNG 1

Podium to Practice: ESMO® 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Barbara Melosky

Icon Chair Speaker

Speakers

Dr. Rosalyn Juergens

Dr. Peter Ellis

Studies / Trials Discussed

LBA74 – Zongertinib as first-line treatment in patients with advanced HER2-mutant NSCLC: Beamion LUNG 1

Studies/trials discussed:

LBA74 – Zongertinib as first-line treatment in patients with advanced HER2-mutant NSCLC: Beamion LUNG 1
Tagged